ETF Target Price Analysis: The Invesco FTSE RAFI US 1000 ETF (PRF) has an implied analyst target price of $50.87, indicating a potential upside of 10.85% from its current trading price of $45.89.
Notable Holdings with Upside: Key underlying holdings of PRF, such as Novavax (NVAX), Navient Corp (NAVI), and Herbalife Ltd (HLF), show significant upside potential based on analyst target prices, with NVAX expected to rise by 57.78%, NAVI by 19.54%, and HLF by 16.37%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industries.
Investor Research Importance: Investors are encouraged to conduct further research to assess the validity of analyst targets and to understand the implications of high price targets relative to current trading prices.
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 10.50 USD with a low forecast of 6.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 10.50 USD with a low forecast of 6.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
3 Sell
Hold
Current: 9.750
Low
6.00
Averages
10.50
High
18.00
Current: 9.750
Low
6.00
Averages
10.50
High
18.00
BofA
Underperform
maintain
$6 -> $7
2026-01-20
New
Reason
BofA
Price Target
$6 -> $7
AI Analysis
2026-01-20
New
maintain
Underperform
Reason
BofA raised the firm's price target on Novavax (NVAX) to $7 from $6 and keeps an Underperform rating on the shares after the company announced a non-exclusive license agreement with Pfizer (PFE) for use of Matrix-M adjuvant in vaccine products in up to two infectious disease fields. While the firm thinks the agreement is a positive sign for interest in the technology and the upfront cash is a plus, it sees the cadence of development as an outstanding question and reiterates an Underperform rating as it awaits greater clarity on the expected development timing for assets from licensing agreements, the analyst tells investors.
JPMorgan
Underweight
downgrade
$7 -> $6
2025-11-18
Reason
JPMorgan
Price Target
$7 -> $6
2025-11-18
downgrade
Underweight
Reason
JPMorgan lowered the firm's price target on Novavax to $6 from $7 and keeps an Underweight rating on the shares. The firm sees limited commercial upside for the company with no material pipeline catalysts next year.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NVAX
Unlock Now
B. Riley
B. Riley
Buy
downgrade
$18 -> $16
2025-11-11
Reason
B. Riley
B. Riley
Price Target
$18 -> $16
2025-11-11
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Novavax to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm highlights the company's increasingly diversified revenue streams.
B. Riley
B. Riley
Buy
downgrade
$18 -> $16
2025-11-10
Reason
B. Riley
B. Riley
Price Target
$18 -> $16
2025-11-10
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Novavax to $16 from $18 and keeps a Buy rating on the shares. Novavax's Q3 top and bottom line results were ahead of the Street's expectations, driven by increasingly diversified revenue streams, the analyst tells investors in a research note. The earlier-stage pipeline represents a second engine of value creation, notably four active programs -- C. difficile, shingles, RSV combination, and pandemic flu, the firm adds.
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
